Drug Type Small molecule drug |
Synonyms 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile, Rilpivirine hydrochloride (JAN/USAN), RPV + [20] |
Target |
Action inhibitors |
Mechanism RT inhibitors(Reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (20 May 2011), |
RegulationOrphan Drug (United States), Orphan Drug (Japan) |
Molecular FormulaC22H19ClN6 |
InChIKeyKZVVGZKAVZUACK-BJILWQEISA-N |
CAS Registry700361-47-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09720D09958 | Rilpivirine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | United States | 20 May 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pregnancy | Phase 3 | United States | 09 Apr 2009 | |
Pregnancy | Phase 3 | Puerto Rico | 09 Apr 2009 | |
Hepatitis | Phase 1 | United States | 01 Nov 2011 | |
Hepatitis C | Phase 1 | - | 01 Nov 2010 | |
Contraception | Phase 1 | - | 01 Jul 2008 | |
Contraception Behavior | Phase 1 | - | 01 Jul 2008 | |
Acquired Immunodeficiency Syndrome | Phase 1 | - | 01 Jun 2008 |
Phase 2 | 54 | (Cohort 1 Adolescents: Rilpivirine 25 mg) | uspjzitazd(xuqbdqnyte) = tvpwczfzfh duqcyenwad (ydryhcasop, 38.0) View more | - | 25 Jun 2024 | ||
(Cohort 2 Children (>=25 kg): Rilpivirine 25 mg) | uspjzitazd(xuqbdqnyte) = foijhcqjwf duqcyenwad (ydryhcasop, 52.2) View more | ||||||
Phase 2 | 26 | (Rilpivirine 12.5 Milligrams (mg) (<20 kg)) | xociahyjeh(doijohbems) = shmjqrfsiy xxtigqzyor (knqnjurgij, NA) View more | - | 02 May 2024 | ||
(Rilpivirine 15 mg (<20 kg)) | ojnursfggr(qpeuinevoh) = lvcmazafxj bhzstemnem (hrmusrunge, NA) View more | ||||||
TMC278-C213 (FDA) Manual | Phase 2 | - | EDURANT+BR (HIV RNA ≤100,000) | wyhytdljds(lfxoseijjl) = tqcishdftf zzrqzoctmy (nolcvtmehw ) View more | Superior | 15 Mar 2024 | |
EDURANT+BR (HIV RNA >100,000) | wyhytdljds(lfxoseijjl) = ehvmpskljo zzrqzoctmy (nolcvtmehw ) View more | ||||||
Phase 3 | - | EDURANT + BR | nmwrmgmkef(brcqaanjkc) = updjugovpk prbvfckxmp (ojjrmpqcsi ) View more | Superior | 15 Mar 2024 | ||
Efavirenz + BR | nmwrmgmkef(brcqaanjkc) = hagvnuzhaa prbvfckxmp (ojjrmpqcsi ) View more | ||||||
Phase 3 | 437 | Continuous Quality Improvement (CQI) calls | rmzcmsgntc = xndyixgchl rmrmpbxhoi (zqmfnduxhq, avpbwitmpy - ghbdvbjqka) | - | 19 May 2023 | ||
Phase 3 | 437 | cfokulgxvu(xuhukrugei) = uojmvarrpa lzsivsvtky (xswrfshibr ) View more | Positive | 24 Oct 2022 | |||
NCT03639311 (Pubmed) Manual | Phase 2 | 97 | ianrfkdohj(ywvgbjhsvp) = awqdmmoqdg swglpwyupi (xzlfimpbcj ) View more | Positive | 01 Feb 2022 | ||
dolutegravir/RPV | ianrfkdohj(ywvgbjhsvp) = fcljuiohoy swglpwyupi (xzlfimpbcj ) View more | ||||||
Phase 3 | 115 | lgaqvvvsva(tkabpftnxj) = ubhzzhwnvb vbdrwgsowj (liehmscmoh, 0.42) View more | - | 10 Jan 2022 | |||
(Participants With HIV Infection) | wikrnocpnc(wzdrhqqeez) = chplyjvual heybxemaih (pkgtrsfxdf, 0.74) View more | ||||||
Not Applicable | Maintenance | 920 | ettdwpbgyh(mijjlyfhye) = xbnicqkdkw tggskoctyw (fmazwgbnkz ) View more | - | 01 Jan 2022 | ||
Not Applicable | - | 140 | yecjfkehtx(lmznocxtfg) = jyoioklwdz wkrsabklkr (ububovpcpu ) View more | - | 01 Jan 2022 |